Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05454956 · ClinicalTrials.gov registry record · Phase 2
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
A Phase 2 study, sponsored by Tarsus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT05454956 is a Phase 2 study that has completed, run by Tarsus Pharmaceuticals. The registered enrollment target is 39 participants.
The verdict
NCT05454956, a Phase 2 study, has completed, sponsored by Tarsus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
Interventions
- DRUG TP-03
- DRUG TP-03 Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2023-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05454956
The ClinicalTrials.gov registry entry for NCT05454956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tarsus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TP-03 is the first listed.
NCT05454956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05454956 about?
NCT05454956 is a clinical study titled "Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD". The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
What is the current status of trial NCT05454956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2022-08-03. Estimated completion is 2023-05-18.
What interventions are being tested in trial NCT05454956?
The interventions under investigation include: TP-03 (DRUG), TP-03 Vehicle (DRUG).
Who is sponsoring clinical trial NCT05454956?
This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.